Publications (78) EMILIA MARÍA BARCIA HERNÁNDEZ publications

2023

  1. Antiparkinsonian Agents in Investigational Polymeric Micro- and Nano-Systems

    Pharmaceutics, Vol. 15, Núm. 1

  2. Análisis farmacocinético poblacional de digoxina en pacientes ancianos

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  3. Can covid-19 be classified among the culprits of neurodegeneration and accelerators of neurodegenerative diseases? Has a new delinquent for neurodegenerative diseases being found?

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  4. Capacitación de alumnos de pregrado en la generación de contenidos divulgativos de Farmacia y Tecnología Farmacéutica para su difusión en entornos virtuales

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  5. Effect of Clindamycin on Intestinal Microbiome and Miltefosine Pharmacology in Hamsters Infected with Leishmania infantum

    Antibiotics, Vol. 12, Núm. 2

  6. Population Pharmacokinetics of Digoxin in Nonagenarian Patients: Optimization of the Dosing Regimen

    Clinical Pharmacokinetics, Vol. 62, Núm. 12, pp. 1725-1738

  7. XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones lit. ed.

    Sociedad Española de Farmacia Industrial y Galénica

2022

  1. A comparison of pharmacokinetics software for therapeutic drug monitoring of piperacillin in patients with severe infections

    European Journal of Hospital Pharmacy

  2. Amikacin pharmacokinetics in elderly patients with severe infections

    European Journal of Pharmaceutical Sciences, Vol. 175

  3. Aplicación de las TIC en asignaturas teórico-prácticas del grado en Farmacia: tecnología farmacéutica y biofarmacia y farmacocinética

    Jornada «Aprendizaje Eficaz con TIC en la UCM» (Universidad Complutense de Madrid), pp. 43-53

  4. Application of neurotoxin- And pesticide-induced animal models of Parkinson's disease in the evaluation of new drug delivery systems

    Acta Pharmaceutica, Vol. 72, Núm. 1, pp. 35-58

  5. Celecoxib Microparticles for Inhalation in COVID-19-Related Acute Respiratory Distress Syndrome

    Pharmaceutics, Vol. 14, Núm. 7

  6. Functionalization of Morin-Loaded PLGA Nanoparticles with Phenylalanine Dipeptide Targeting the Brain

    Pharmaceutics, Vol. 14, Núm. 11

  7. Leishmania infantum infection does not affect the main composition of the intestinal microbiome of the Syrian hamster

    Parasites and Vectors, Vol. 15, Núm. 1

  8. Micro-and Nano-Systems Developed for Tolcapone in Parkinson’s Disease

    Pharmaceutics, Vol. 14, Núm. 5

  9. Population pharmacokinetics of digoxin in elderly patients: A systematic review

    Farmacia Hospitalaria, Vol. 46, Núm. 6, pp. 359-366

2021

  1. Development and validation of an hplc method for the quantification of morin flavonoid encapsulated within plga nanoparticles

    Current Pharmaceutical Analysis, Vol. 17, Núm. 9, pp. 1178-1187

  2. Doxycycline microparticles for potential use in neurodegenerative diseases

    RESCIFAR Revista Española de Ciencias Farmacéuticas, Vol. 2, Núm. 2, pp. 231-232

  3. Opciones terapéuticas en el tratamiento de la enfermedad de Alzheimer

    RESCIFAR Revista Española de Ciencias Farmacéuticas, Vol. 2, Núm. 1, pp. 23-31

  4. Sulfasalazine microparticles targeting macrophages for the treatment of inflammatory diseases affecting the synovial cavity

    Pharmaceutics, Vol. 13, Núm. 7